Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease
| Status: | Terminated |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/15/2017 |
| Start Date: | December 2003 |
| End Date: | December 2010 |
The Intracoronary Tissue-type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events in Patients With Non-critical Coronary Artery Disease
Coronary artery disease is the leading cause of death in USA. Contemporary cardiac care has
substantially reduced mortality and morbidity in patients with severe coronary artery
disease. However, patients with mild to moderate coronary artery stenosis (<70% stenosis)
often present in the future with life threatening acute coronary syndrome which carries
significant mortality and morbidity. It is difficult to predict outcomes in these patients
before the events because the lack of complete understanding of the mechanisms underlying
acute coronary syndrome and the lack of reliable markers that will predict major adverse
cardiac events (MACE). Tissue-type plasminogen activator (t-PA) is released from endothelial
cells and a major factor that prevent thrombosis in the coronary artery, the cause of acute
coronary syndrome. Endothelial dysfunction impairs t-PA release. Therefore, we hypothesize
that patients with impaired coronary artery t-PA release will have significantly higher risk
for future MACE due to intrinsic fibrinolytic dysfunction that leads to increased thrombosis
risk.
To test this hypothesis, we will determine whether intrinsic endothelial fibrinolytic
dysfunction predicts MACE in patients with non-significant CAD. The study will measure t-PA
release mediated by bradykinin, a major mediator for t-PA release. This will involve infusion
of bradykinin into left main coronary artery of individuals who have undergone routine
cardiac catheterization (clinically indicated). We will take blood samples from the coronary
sinus and measure t-PA and plasminogen activator inhibitor-1 antigen and activity levels.
substantially reduced mortality and morbidity in patients with severe coronary artery
disease. However, patients with mild to moderate coronary artery stenosis (<70% stenosis)
often present in the future with life threatening acute coronary syndrome which carries
significant mortality and morbidity. It is difficult to predict outcomes in these patients
before the events because the lack of complete understanding of the mechanisms underlying
acute coronary syndrome and the lack of reliable markers that will predict major adverse
cardiac events (MACE). Tissue-type plasminogen activator (t-PA) is released from endothelial
cells and a major factor that prevent thrombosis in the coronary artery, the cause of acute
coronary syndrome. Endothelial dysfunction impairs t-PA release. Therefore, we hypothesize
that patients with impaired coronary artery t-PA release will have significantly higher risk
for future MACE due to intrinsic fibrinolytic dysfunction that leads to increased thrombosis
risk.
To test this hypothesis, we will determine whether intrinsic endothelial fibrinolytic
dysfunction predicts MACE in patients with non-significant CAD. The study will measure t-PA
release mediated by bradykinin, a major mediator for t-PA release. This will involve infusion
of bradykinin into left main coronary artery of individuals who have undergone routine
cardiac catheterization (clinically indicated). We will take blood samples from the coronary
sinus and measure t-PA and plasminogen activator inhibitor-1 antigen and activity levels.
Tissue-type Plasminogen Activator (tPA) is a protein in the blood which breaks down clots and
plays an important role in preventing myocardial infarction. It is produced by the
endothelial cell lining of the blood vessels. Previous studies demonstrate that t-PA is
released in response to the hormones bradykinin and acetylcholine. Impaired t-PA release upon
bradykinin stimulation may indicate endothelial dysfunction that leads to the development of
acute coronary syndrome. In this project, we will determine whether impaired t-PA release can
predict future occurrence of acute coronary syndrome. The study will involve individuals
getting routine left heart cardiac catheterizations (indication for cardiac catheterization
is solely based on clinical indication). Prior to the procedure, patient will have two blood
samples (5 ml each) collected from their forearm before and after 2 minutes blood pressure
cuff inflation on their arm. After routine diagnostic cardiac catheterization and there is no
severe coronary artery stenosis (<70% stenosis), research protocol will be initiated. Study
includes infusion with increasing doses of bradykinin into their left main coronary artery,
and sample small amounts of blood from their coronary sinus (15 ml total).
plays an important role in preventing myocardial infarction. It is produced by the
endothelial cell lining of the blood vessels. Previous studies demonstrate that t-PA is
released in response to the hormones bradykinin and acetylcholine. Impaired t-PA release upon
bradykinin stimulation may indicate endothelial dysfunction that leads to the development of
acute coronary syndrome. In this project, we will determine whether impaired t-PA release can
predict future occurrence of acute coronary syndrome. The study will involve individuals
getting routine left heart cardiac catheterizations (indication for cardiac catheterization
is solely based on clinical indication). Prior to the procedure, patient will have two blood
samples (5 ml each) collected from their forearm before and after 2 minutes blood pressure
cuff inflation on their arm. After routine diagnostic cardiac catheterization and there is no
severe coronary artery stenosis (<70% stenosis), research protocol will be initiated. Study
includes infusion with increasing doses of bradykinin into their left main coronary artery,
and sample small amounts of blood from their coronary sinus (15 ml total).
Inclusion Criteria:
1. Age >18 year old male and female patients
2. All patients are referred for elective cardiac catheterization based on clinical
indication
3. Cath shows mild or moderate (<70% stenosis) CAD that does not require mechanical
intervention
Exclusion Criteria:
1. Severe stenosis requires intervention.
2. Significant left main coronary artery disease (>40%).
3. Acute MI or acute coronary syndrome with enzyme elevation or ischemic EKG changes
4. Patients with severe left ventricular dysfunction (EF<35%)
5. Prior history of myocardial infarction
6. History of stroke within 3 months.
7. Recent history of thrombolytic
8. History of coronary intervention within previous 6 months.
9. Patients with history of coronary spasm
10. Patients with congestive heart failure (class III and IV).
We found this trial at
1
site
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
